| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7651937 | Revue Francophone des Laboratoires | 2013 | 9 Pages |
Abstract
Although the nature of the underlying oncogenic events in HCL is unknown, the recent identification of BRAFV600E mutation in HCL represents a way to introduce BRAF inhibitors in the treatment of HCL patients, who are refectory to purine analogs.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Xavier Troussard, Abdelkader Belmekki, Michèle Malet, Edouard Cornet,